m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG04166)
Name |
APG-101
|
||||
---|---|---|---|---|---|
Synonyms |
CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix
Click to Show/Hide
|
||||
Status |
Phase 2
|
||||
TTD Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Apoptosis mediating surface antigen FAS (FAS)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-101. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of APG-101 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [1], [2] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-101 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [2], [3] | ||
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-101. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of APG-101 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [2], [4] | ||
References